{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T23:25:58Z","timestamp":1785281158544,"version":"3.55.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,10]],"date-time":"2024-03-10T00:00:00Z","timestamp":1710028800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-genitourinary-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.clgc.2024.102064","type":"journal-article","created":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T09:32:33Z","timestamp":1709890353000},"page":"102064","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Therapeutic Drug Monitoring for Tyrosine Kinase Inhibitors in Metastatic Renal Cell Carcinoma"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0784-3206","authenticated-orcid":false,"given":"Jakob N.","family":"Henriksen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte U.","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels","family":"Fristrup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.clgc.2024.102064_bib0001","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21551","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"10.1016\/j.clgc.2024.102064_bib0002","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMra1601333","article-title":"Systemic therapy for metastatic renal-cell carcinoma","volume":"376","author":"Choueiri","year":"2017","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.clgc.2024.102064_bib0003","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.ejca.2013.10.010","article-title":"Improved overall survival after implementation of targeted therapy for patients with metastatic renal cell carcinoma: results from the Danish Renal Cancer Group (DARENCA) study-2","volume":"50","author":"Soerensen","year":"2014","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1016\/j.clgc.2024.102064_bib0004","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1517\/14740338.2012.712108","article-title":"Safety and tolerability of pazopanib in the treatment of renal cell carcinoma","volume":"11","author":"Zivi","year":"2012","journal-title":"Expert Opin Drug Saf"},{"issue":"14","key":"10.1016\/j.clgc.2024.102064_bib0005","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.clgc.2024.102064_bib0006","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s00228-013-1504-x","article-title":"Therapeutic drug monitoring for tomorrow","volume":"69","author":"Eliasson","year":"2013","journal-title":"Eur J Clin Pharmacol"},{"issue":"12","key":"10.1016\/j.clgc.2024.102064_bib0007","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1016\/j.ejca.2014.04.015","article-title":"Review of therapeutic drug monitoring of anticancer drugs part two\u2014targeted therapies","volume":"50","author":"Widmer","year":"2014","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.clgc.2024.102064_bib0008","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/FTD.0000000000000699","article-title":"Therapeutic drug monitoring of targeted anticancer protein kinase inhibitors in routine clinical use: a critical review","volume":"42","author":"Cardoso","year":"2020","journal-title":"Ther Drug Monit"},{"issue":"12","key":"10.1016\/j.clgc.2024.102064_bib0009","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/j.annonc.2021.09.014","article-title":"ESMO Clinical Practice Guideline update on the use of immunotherapy in early stage and advanced renal cell carcinoma","volume":"32","author":"Powles","year":"2021","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.clgc.2024.102064_bib0010","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s00280-009-1170-y","article-title":"Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic\/pharmacodynamic meta-analysis","volume":"66","author":"Houk","year":"2010","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"10.1016\/j.clgc.2024.102064_bib0011","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/fcp.12327","article-title":"Drug monitoring of sunitinib in patients with advanced solid tumors: a monocentric observational French study","volume":"32","author":"Cabel","year":"2018","journal-title":"Fundam Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.clgc.2024.102064_bib0012","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1007\/s00280-022-04432-4","article-title":"Feasibility of therapeutic drug monitoring of sunitinib and its implications on response and toxicity in patients with metastatic renal cell cancer","volume":"89","author":"Gandhi","year":"2022","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"10.1016\/j.clgc.2024.102064_bib0013","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s00280-017-3362-1","article-title":"Dose individualization of sunitinib in metastatic renal cell cancer: toxicity-adjusted dose or therapeutic drug monitoring","volume":"80","author":"Sabanathan","year":"2017","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"10.1016\/j.clgc.2024.102064_bib0014","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s11523-014-0349-2","article-title":"Association of drug exposure with toxicity and clinical response in metastatic renal cell carcinoma patients receiving an attenuated dosing regimen of sunitinib","volume":"10","author":"Teo","year":"2015","journal-title":"Target Oncol"},{"issue":"9","key":"10.1016\/j.clgc.2024.102064_bib0015","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/psp4.12210","article-title":"Population modeling integrating pharmacokinetics, pharmacodynamics, pharmacogenetics, and clinical outcome in patients with sunitinib-treated cancer","volume":"6","author":"Diekstra","year":"2017","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"3","key":"10.1016\/j.clgc.2024.102064_bib0016","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1248\/bpb.b14-00636","article-title":"Pharmacokinetic-pharmacodynamic analysis of sunitinib-induced thrombocytopenia in Japanese patients with renal cell carcinoma","volume":"38","author":"Nagata","year":"2015","journal-title":"Biol Pharm Bull"},{"issue":"4","key":"10.1016\/j.clgc.2024.102064_bib0017","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.clgc.2015.01.007","article-title":"Assessment of sunitinib-induced toxicities and clinical outcomes based on therapeutic drug monitoring of sunitinib for patients with renal cell carcinoma","volume":"13","author":"Noda","year":"2015","journal-title":"Clin Genitourin Cancer"},{"issue":"2","key":"10.1016\/j.clgc.2024.102064_bib0018","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/bcp.14332","article-title":"The relationship between sunitinib exposure and both efficacy and toxicity in real-world patients with renal cell carcinoma and gastrointestinal stromal tumour","volume":"87","author":"Westerdijk","year":"2021","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"10.1016\/j.clgc.2024.102064_bib0019","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1007\/s10147-018-1302-7","article-title":"Relationships between sunitinib plasma concentration and clinical outcomes in Japanese patients with metastatic renal cell carcinoma","volume":"23","author":"Takasaki","year":"2018","journal-title":"Int J Clin Oncol"},{"issue":"6","key":"10.1016\/j.clgc.2024.102064_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100312","article-title":"Association of cabozantinib pharmacokinetics, progression and toxicity in metastatic renal cell carcinoma patients: results from a pharmacokinetics\/pharmacodynamics study","volume":"6","author":"Cerbone","year":"2021","journal-title":"ESMO Open"},{"issue":"2","key":"10.1016\/j.clgc.2024.102064_bib0021","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1002\/ijc.33797","article-title":"Exposure-toxicity relationship of cabozantinib in patients with renal cell cancer and salivary gland cancer","volume":"150","author":"Krens","year":"2022","journal-title":"Int J Cancer"},{"issue":"1","key":"10.1016\/j.clgc.2024.102064_bib0022","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1186\/s12885-022-09338-1","article-title":"Exposure-response analyses of cabozantinib in patients with metastatic renal cell cancer","volume":"22","author":"Krens","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clgc.2024.102064_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchromb.2020.121968","article-title":"A simple and rapid liquid chromatography-mass spectrometry method to assay cabozantinib in plasma: application to therapeutic drug monitoring in patients with renal cell carcinoma","volume":"1138","author":"Ferrer","year":"2020","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"issue":"10","key":"10.1016\/j.clgc.2024.102064_bib0024","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1038\/bjc.2014.503","article-title":"Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma","volume":"111","author":"Suttle","year":"2014","journal-title":"Br J Cancer"},{"issue":"6","key":"10.1016\/j.clgc.2024.102064_bib0025","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1007\/s00280-017-3463-x","article-title":"Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimization","volume":"80","author":"Verheijen","year":"2017","journal-title":"Cancer Chemother and Pharmacol"},{"issue":"5","key":"10.1016\/j.clgc.2024.102064_bib0026","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1248\/bpb.b19-00560","article-title":"Possibility for dose optimization of pazopanib from its plasma concentration in Japanese patients with cancer","volume":"43","author":"Tanaka","year":"2020","journal-title":"Biol Pharm Bull"},{"issue":"2","key":"10.1016\/j.clgc.2024.102064_bib0027","doi-asserted-by":"crossref","first-page":"e306","DOI":"10.1016\/j.clgc.2018.12.001","article-title":"Exploratory investigation of target pazopanib concentration range for patients with renal cell carcinoma","volume":"17","author":"Noda","year":"2019","journal-title":"Clin Genitourin Cancer"},{"issue":"5","key":"10.1016\/j.clgc.2024.102064_bib0028","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1002\/jcph.73","article-title":"Axitinib in metastatic renal cell carcinoma: results of a pharmacokinetic and pharmacodynamic analysis","volume":"53","author":"Rini","year":"2013","journal-title":"J Clin Pharmacol"},{"issue":"7","key":"10.1016\/j.clgc.2024.102064_bib0029","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1093\/annonc\/mdv103","article-title":"Axitinib dose titration: analyses of exposure, blood pressure and clinical response from a randomized phase II study in metastatic renal cell carcinoma","volume":"26","author":"Rini","year":"2015","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.clgc.2024.102064_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2022.03.006","article-title":"Axitinib trough concentration and its influence on the efficacy and toxicity of second-line renal cell carcinoma treatment","volume":"20","author":"Synowiec","year":"2022","journal-title":"Clin Genitourin Cancer"},{"issue":"2","key":"10.1016\/j.clgc.2024.102064_bib0031","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s10637-020-01023-z","article-title":"Absorption of the orally active multikinase inhibitor axitinib as a therapeutic index to guide dose titration in metastatic renal cell carcinoma","volume":"39","author":"Fukudo","year":"2021","journal-title":"Invest New Drugs"},{"issue":"6","key":"10.1016\/j.clgc.2024.102064_bib0032","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1007\/s10637-019-00743-1","article-title":"Axitinib pharmacologic therapeutic monitoring reveals severe under-exposure despite titration in patients with metastatic renal cell carcinoma","volume":"37","author":"Beinse","year":"2019","journal-title":"Invest New Drugs"},{"issue":"26","key":"10.1016\/j.clgc.2024.102064_bib0033","doi-asserted-by":"crossref","first-page":"43458","DOI":"10.18632\/oncotarget.16465","article-title":"In-vivo relation between plasma concentration of sorafenib and its safety in Chinese patients with metastatic renal cell carcinoma: a single-center clinical study","volume":"8","author":"Mai","year":"2017","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.clgc.2024.102064_bib0034","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s40262-013-0108-z","article-title":"Exposure-toxicity relationship of sorafenib in Japanese patients with renal cell carcinoma and hepatocellular carcinoma","volume":"53","author":"Fukudo","year":"2014","journal-title":"Clin Pharmacokinet"},{"issue":"13","key":"10.1016\/j.clgc.2024.102064_bib0035","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1158\/1078-0432.CCR-17-2652","article-title":"Pazopanib exposure relationship with clinical efficacy and safety in the adjuvant treatment of advanced renal cell carcinoma","volume":"24","author":"Sternberg","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.clgc.2024.102064_bib0036","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s00228-020-03014-8","article-title":"Therapeutic drug monitoring of oral targeted antineoplastic drugs","volume":"77","author":"Mueller-Schoell","year":"2021","journal-title":"Eur J Clin Pharmacol"},{"issue":"1-02","key":"10.1016\/j.clgc.2024.102064_bib0037","first-page":"9","article-title":"Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017","volume":"51","author":"Hiemke","year":"2018","journal-title":"Pharmacopsychiatry"},{"issue":"13","key":"10.1016\/j.clgc.2024.102064_bib0038","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.1158\/1078-0432.CCR-18-0291","article-title":"Goldilocks dosing of TKIs: a dose that is just right leads to optimal outcomes","volume":"24","author":"Rini","year":"2018","journal-title":"Clin Cancer Res"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767324000375?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767324000375?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T08:00:06Z","timestamp":1717660806000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767324000375"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S1558767324000375"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2024.102064","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic Drug Monitoring for Tyrosine Kinase Inhibitors in Metastatic Renal Cell Carcinoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2024.102064","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102064"}}